Komori
Kaken Pharmaceutical (4521) · FactWorsenedLatest Results (2026-11-09): "Restated"

Recording of overseas revenue

First written in FY2019-Q3. 9 of 28 entries say "Softened", first in FY2020-Q3. Latest entry: 2026-11-09.

28entries
8years
6from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorse2019: 420192020: 320202021: 420212022: 420222023: 320232024: 220242025: 120252026: 72026
Same theme, other companies
Expansion and Contraction of Overseas Sales and Geographic DiversificationA theme 34 companies write about · 3 as a headwind · 15 as a tailwind

The whole theme swung hardest in 2023: 3 of 28 companies on the "Worse" side.

1 other company's latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 34 companies compared. The sentences above are computed from all 34.
Full recordFilings, disclosures and news, newest first
  1. FY2026WorsenedAnnual report

    「Overseas sales were ¥12,840 million, down 51.7% year on year from the same period of the previous year.」

    Overseas sales were ¥12,840 million, down 51.7% year on year, mainly due to the reversal of the previous fiscal year's upfront contractual income, among other factors.
  2. 2026-05-13First statedResults

    「2027年 3月期の連結業績予想(2026年 4月 1日~2027年 3月31日) 通期 89,900 17.0 7,900 ― 8,600 ― 6,500 203.1 171.65」

    2026年3月期の営業損失・経常損失から、2027年3月期は売上高89,900百万円、営業利益7,900百万円、経常利益8,600百万円、親会社株主に帰属する当期純利益6,500百万円を予想している。
  3. FY2026-H1WorsenedAnnual report

    「Overseas sales were ¥5,199 million, down 68.6% from the previous interim consolidated accounting period.」

    Overseas sales were ¥5,199 million, down 68.6% from the same interim period of the previous year. The decline was attributed to the reversal of upfront contractual income related to NM26 in the previous interim period, among other factors.
  4. FY2025-H1AdvancedAnnual report

    「Overseas sales were ¥16,550 million, up 501.7% from the previous interim consolidated accounting period.」

    Overseas sales were ¥16,550 million, an increase of 501.7% from the same interim consolidated accounting period of the previous year. The increase was attributed to an upfront contractual payment related to the transfer of intellectual property for NM26 and higher sales of Jublia and other products.
  5. FY2024-Q3SoftenedAnnual report

    「Overseas sales were ¥4,045 million, down 12.4% year on year from the same quarter of the previous year.」

    Overseas sales continued to decline, falling 12.4% year on year, although the decrease narrowed from 18.7% in the previous quarter.
  6. FY2024-Q2WorsenedAnnual report

    「Overseas sales were ¥2,750 million, down 18.7% year on year from the same quarter of the previous year.」

    Overseas sales fell 18.7% year on year, reversing from the growth trend that had continued from the previous fiscal year to a decline.
  7. FY2024-Q1SoftenedAnnual report

    「Overseas sales were ¥1,518 million, up 2.0% year on year from the same quarter of the previous year.」

    Overseas sales maintained a 2.0% year-on-year increase, although the growth rate declined substantially from a 57.6% increase in the first quarter of the previous fiscal year.
  8. FY2023-Q3SoftenedAnnual report

    「Overseas sales were ¥4,616 million, up 11.8% year on year from the same quarter of the previous year.」

    Overseas sales maintained growth, increasing 11.8% year on year, although the growth rate declined from a 36.9% increase in the cumulative second quarter of the previous fiscal year.
  9. FY2023-Q2SoftenedAnnual report

    「Overseas sales were ¥3,385 million, up 16.7% year on year from the same quarter of the previous year.」

    Overseas sales maintained growth, increasing 16.7% year on year, although the growth rate declined from a 57.6% year-on-year increase in the first quarter of the previous fiscal year and 36.9% in the second quarter of the previous fiscal year.
  10. FY2023-Q1AdvancedAnnual report

    「Overseas sales were ¥1,489 million, up 57.6% year on year from the same quarter of the previous year.」

    Overseas sales were ¥1,489 million, up 57.6% from the same quarter of the previous year. Sales reversed from a 20.5% year-on-year decrease in the first quarter of the previous fiscal year to an increase.
  11. FY2022AdvancedAnnual report

    「Overseas sales were ¥6,956 million, up 41.7% year on year from the same period of the previous year.」

    Overseas sales were ¥6,956 million, up 41.7% year on year, reversing from a decline in the previous fiscal year to an increase. Growth in overseas sales of Jublia was cited as a factor behind the increase in sales.
  12. FY2022-Q3SoftenedAnnual report

    「Overseas sales were ¥4,129 million, up 22.4% year on year from the same quarter of the previous year.」

    Overseas sales were ¥4,129 million, up 22.4% year on year, maintaining growth, although the growth rate declined from a 36.9% year-on-year increase in the cumulative second quarter of the previous fiscal year.
  13. FY2022-Q2AdvancedAnnual report

    「Overseas sales were ¥2,901 million, up 36.9% year on year from the same quarter of the previous year.」

    Overseas sales were ¥2,901 million, up 36.9% year on year, reversing from a 20.5% year-on-year decrease in the first quarter of the previous fiscal year to an increase.
  14. FY2022-Q1WorsenedAnnual report

    「Overseas sales were ¥945 million, down 20.5% year on year from the same quarter of the previous year.」

    Overseas sales reversed from a 27.8% year-on-year increase in the first quarter of the previous fiscal year to a 20.5% year-on-year decrease.
  15. FY2021SoftenedAnnual report

    「Overseas sales were ¥4,908 million, down 38.7% year on year, mainly due to lower sales related to LOPION in China.」

    Overseas sales fell 38.7% year on year. Although the decline narrowed from 44.7% in the third quarter, overseas sales continued to decline for the full year.
  16. FY2021-Q3WorsenedAnnual report

    「Overseas sales were ¥3,372 million, down 44.7% year on year from the same quarter of the previous year.」

    Overseas sales fell 44.7% year on year, compared with a 29.7% decline in the previous quarter, indicating a widening decrease. Overseas sales continued to decline.
  17. FY2021-Q2WorsenedAnnual report

    「Overseas sales were ¥2,119 million, down 28.5% year on year from the same quarter of the previous year.」

    Overseas sales turned from a 27.8% year-on-year increase in the previous quarter to a 28.5% year-on-year decrease. The declining trend in overseas sales has again become evident.
  18. FY2021-Q1AdvancedAnnual report

    「Overseas revenue was ¥1,188 million, up 27.8% year on year.」

    Overseas revenue was ¥1,188 million, up 27.8% year on year, improving from the 56.1% year-on-year decline in the first quarter of the previous fiscal year.
  19. FY2020-Q3SoftenedAnnual report

    「Overseas revenue was ¥6,094 million, down 1.0% year on year.」

    Overseas revenue remained below the previous year, down 1.0% year on year, but the decline narrowed from 29.7% year on year in the previous quarter.
  20. FY2020-Q2RestatedAnnual report

    「Overseas revenue was ¥2,965 million, down 29.7% year on year.」

    Overseas revenue was ¥2,965 million, down 29.7% year on year. The downward trend in overseas revenue continued.
  21. FY2020-Q1WorsenedAnnual report

    「Overseas revenue was ¥930 million, down 56.1% year on year.」

    Overseas revenue was ¥930 million, representing a substantial 56.1% decline from the same quarter of the previous year.
  22. FY2019AdvancedAnnual report

    「Overseas revenue was ¥9,016 million.」

    Overseas revenue was ¥9,016 million for the fiscal year, updated from ¥6,156 million in the cumulative third quarter to the full-year result.
  23. FY2019-Q3First statedAnnual report

    「Overseas revenue was ¥6,156 million.」

    The fact that overseas revenue was ¥6,156 million is recorded as an independent fact for the first time in this filing.
Moved together

"Decline in Real Estate Business Revenue and Profit" moved the same way as this thread, in the same document, in 10 of its 27 moves.

10109777★123456
  1. ★This thread
  2. 1Decline in Real Estate Business Revenue and Profit10×
  3. 2Impact of drug price revisions and lower income from overseas licensees10×
  4. 3Declines in operating profit and net profit9×
  5. 4Continuation of R&D investment7×
  6. 5Jublia sales growth7×
  7. 6Decline in Cash Flow from Operating Activities7×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
Kaken Pharmaceutical's next results are scheduled for 2026-11-09. Read the earnings preview It last moved in the Results of 2026-11-09: "Restated".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.